Eris Lifesciences (ERIS) | Stock Overview & Key Data
Eris Lifesciences Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,910.00 on June 9, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | 1.12% | -4.39% | 20.53% | -2.62% | -1.58% | -18.17% | 77.37% | -2.17% | -2.17% | -2.17% | -2.17% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | 0.54% | 2.81% | 39.46% | 3.75% | 13.25% | 30.36% | 489.12% | 756.32% | 2,077.38% | 16,439.72% | 20,028.75% |
|
Natco Pharma
NATCOPHARM
|
191.91B Mid-cap | -2.38% | -29.31% | -10.42% | -6.36% | -4.57% | -5.35% | 37.05% | -21.16% | 69.86% | 1,522.04% | 4,430.15% |
Ownership & Short Interest
Calculate Your Eris Lifesciences Investment Returns
Long-Term Investment Performance Analysis
Eris Lifesciences stock price in Jun 2017 was ₹601.50, A ₹1,000.00 lump sum investment in Eris Lifesciences made 9 years ago would be worth approximately ₹2,301.58 today, representing a strong return of 130.16%. This translates to an annualized return (CAGR) of 9.74%.
8 Years 11 Months Investment Scenario (Jun 2017 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ERIS's 52-week high and low?
- In the last 52 weeks, Eris Lifesciences reached a high of ₹1,900.00 (on June 16, 2025) and a low of ₹1,200.00 (on N/A).
- What is the market cap and P/E ratio for ERIS?
- Curious about Eris Lifesciences's size and valuation? Its market capitalization stands at 193.36B. When it comes to valuation, the P/E ratio (trailing twelve months) is 44.25, and the forward P/E (looking ahead) is 27.76.
- Does ERIS pay dividends? If so, what's the yield?
- Yes, Eris Lifesciences is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.41%, and the company has paid an average of ₹4.90 per share annually over the past 3 years.
- Who are Eris Lifesciences's main competitors or similar companies to consider before investing?
When looking at Eris Lifesciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -18.17% 77.37% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 30.36% 489.12% Natco Pharma
NATCOPHARM191.91B Healthcare Drug Manufacturers - Specialty & Generic -5.35% 37.05% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Eris Lifesciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Eris Lifesciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.75%, the Debt to Equity ratio from the most recent quarter is 68.19, and its Gross Profit Margin stands at 72.12%.
- What is the recent revenue and earnings growth for ERIS?
- Looking at Eris Lifesciences's growth, its revenue over the trailing twelve months (TTM) was INR31B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.90%, and quarterly earnings saw a YoY growth of 19.20%.
- How much of ERIS stock is held by insiders and institutions?
- Wondering who owns Eris Lifesciences stock? Company insiders (like executives and directors) hold about 68.05% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 21.83%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.